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Zhang and colleagues have recently published a
systematic review and meta-analysis of six studies and
conclude that ‘gastric tonometry guided therapy can
reduce total mortality in critically ill patients’. So why
did gastric tonometry come and go, and what can we
learn from this piece of modern history?energy. Anaerobic metabolism generates lactic acid andGastric tonometry measures the balance between alveolar
ventilation, gastric blood flow, and metabolism [1,2]. In the
1990s, gastric tonometry was a fashionable clinical monitor
and was incorporated into numerous laboratory and clinical
trials [3-6]. Then, soon after a small randomised controlled
trial (RCT) of just over 200 patients reported no impact on
ICU mortality when gastric tonometry was used to
guide therapy, it seemed to disappear as a clinical
tool [7]. However, Zhang and colleagues have recently
published a systematic review and meta-analysis of these
six studies and conclude that ‘gastric tonometry guided
therapy can reduce total mortality in critically ill patients’
[1]. So why did gastric tonometry come and go, and what
can we learn from this piece of modern history?
Hollow viscus tonometry is a long-established technique.
Lavaging a hollow viscus such as the gall bladder or
gastrointestinal tract allows an estimate of the partial
pressure of gas tension in the wall of the viscus by
analysis of the lavage. It was deployed in the stomach
over decades, evolving from sampling gastric juice to the
use of condoms attached to nasogatric tubes and eventually
bespoke modified nasogatric tubes that incorporated a
silicone balloon and sampling line. Manual saline
tonometry required the balloon to be filled with 2.5 mL
saline and, following a dwell time of up to 90 minutes,
sampling and analysis using a blood-gas analyser [3-6].Correspondence: m.mythen@ucl.ac.uk
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unless otherwise stated.Attention was initially focused on the calculation of ‘gastric
intra-mucosal pH’ (or ‘pHi’) by using the gut lumen carbon
dioxide (CO2) measured by tonometry and the calculated
arterial bicarbonate concentration from an arterial sample
drawn at the same time. The theory was that, during
periods of reduced gastric blood flow, a critical level would
be reached below which anaerobic metabolism would be
the dominant metabolic pathway for the generation of
causes the accumulation of CO2.
The first bespoke gastric tonometer was probably
launched prematurely as a number of technical glitches,
such as the impact of poor sampling technique and
temperature on CO2 tension, needed to be resolved
post-launch. Despite these glitches, ‘pHi’ measurement
became popular in clinical observational studies and was
demonstrated in major surgery, trauma, and the ICU to
be a highly sensitive but less specific predictor of a poor
outcome [3-6]. Doubt was cast on the utility of ‘pHi’ as it
incorporated both global acid–base balance and regional
partial pressure of CO2 (PCO2) [1,8]. Thus, a metabolic
acidosis without an excess accumulation of gastric CO2
could result in a low ‘pHi’ that was simply a repackaging
of base excess [2,8]. Finally, automated air tonometry was
launched [9]. The bespoke tonometer tube was unchanged
but now air rather than saline was used to fill the balloon.
This facilitated quicker full equilibration and automated
sampling and measurement by using a modified end-tidal
CO2 infra-red analyser [9]. The calculation of ‘pHi’ was
abandoned and interest turned to the rise in gastric partial
pressure of CO2 compared with either the arterial partial
pressure of CO2 or end-tidal partial pressure of CO2,
referred to as the PCO2 ‘gap’ or ‘gradient’. This again proved
to be highly predictive of a poor outcome, particularly in
major surgery [9]. So now, at last, we thought we had a
user-friendly, automated, robust surrogate measure of
‘end-organ perfusion’ and a growing understanding of
the technique and the separation between global
haemodynamic variables and splanchnic blood flow. Itis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Mythen Critical Care  (2015) 19:172 Page 2 of 2was demonstrated, for example, that haemorrhage in adult
volunteers could be detected by gastric tonometry when
commonly measured haemodynamic variables remained
unchanged [10] and that if critically ill patients had an
abnormal PCO2 ‘gap’ they failed to produce gastric acid
following pentagastrin stimulation [11]. Furthermore,
gut-directed therapy could maintain or correct PCO2
‘gap’ [4,12]. So where did it all go wrong?
I think there were a number of factors. Gastric tonometry
was made commercially available before all of the meth-
odological issues had been resolved and this resulted in
negative press. Furthermore, evidence-based medicine and
the demand for ‘proof ’ of safety and efficacy from large
RCTs were just emerging. How one should apply these
standards to monitors of physiological variables was not
and has probably still not been completely resolved. Where
should the burden of proof lie? With manufacturers or the
clinical community? What would be the cost implications
of demanding the equivalent of phase III level of evidence
for monitors? Gastric tonometry was caught up in this
emerging debate and came off second best. Perhaps the
burden lies with the clinical trials, although noble efforts in
their day would now be regarded as inadequately designed
to answer the question ‘does gastric tonometry guided
resuscitation improve ICU survival?’ [1]. The largest of the
six studies randomly assigned just 260 patients—some 10-
to 20-fold fewer than the numbers one might expect to
have to recruit today to answer the same question [1,4].
The recent meta-analysis by Zhang and colleagues con-
cludes (among other things) that ‘in critical care patients,
gastric tonometry guided therapy can reduce total mortal-
ity’ [1]. On reviewing the results, one can see that six small
RCTs were conducted on a diverse range of populations
(surgery, trauma, and the ICU). All of the trials were grossly
underpowered to determine a possible impact on mortality.
However, the point estimates for impact on mortality
(Figure three [1]) all favour the intervention, but the confi-
dence intervals are large and cross the line of unity.
I suggest that if we were starting from this point
today, we would conclude that there is equipoise, sig-
nificant uncertainty, and enough evidence to justify
asking the question ‘does gastric tonometry-guided
therapy reduce total mortality in critically ill patients?’
This question could be answered by a pragmatic,
high-quality RCT with patient-centred outcomes, but
I doubt it will be.
Abbreviations
CO2: Carbon dioxide; PCO2: Partial pressure of carbon dioxide; pHi: Gastric
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